Business Context and Reporting Period
This Form 8-K reports on the completion of Anixa Biosciences, Inc.'s 2026 Annual Meeting of Stockholders held on March 10, 2026. The company is incorporated in Delaware and trades on The NASDAQ Stock Market under the symbol ANIX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
At the Annual Meeting, 20,805,324 shares of the 33,379,505 voting shares entitled to vote were present or represented by proxy. Stockholders approved three key proposals:
- Election of Directors: Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. were re-elected. Notably, while all were re-elected, significant shares were withheld for Dr. Arnold Baskies (1,710,151), Emily Gottschalk (1,886,761), and Lewis H. Titterton, Jr. (1,959,312), compared to Dr. Amit Kumar (218,238).
- Executive Compensation: The company's executive compensation was approved on a non-binding advisory basis. However, the vote was split, with 2,973,752 votes cast against the proposal compared to 6,025,247 votes for.
- Auditor Ratification: The appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending October 31, 2026, was ratified with overwhelming support (20,426,524 votes for vs. 191,432 against).
Guidance, Outlook, and Risks
Management presented a slide deck at the Annual Meeting (attached as Exhibit 99.1), which may be used in future investor communications. The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the standard disclosure of the presentation materials.
Investor Verification Checklist
- Review the specific reasons for the significant number of shares withheld for three of the four director nominees.
- Analyze the substantial "Against" vote (approx. 33% of votes cast) on the executive compensation proposal to understand shareholder sentiment.
- Examine Exhibit 99.1 for any strategic updates or operational milestones discussed during the meeting.
- Verify the company's cash runway and burn rate in the most recent 10-K or 10-Q, as this 8-K contains no financial data.